Background
Rheumatoid arthritis (RA) is a systemic autoimmune disease, characterized by chronic joint inflammation and synovial hyperplasia leading to bone and joint destruction. The life expectancy is lowered and quality of life is decreased in RA patients. So far little is known about the actual disease initiating stimulus; however, extensive research over the last decades have shown that multiple genetic as well as environmental factors interact and trigger the onset of RA [
1,
2]. The autoimmune inflammation of RA is maintained by inappropriate action of macrophages, B-cells, T-cells, and other types of cells leading to dysregulated cytokine/chemokine production. The synovial inflammation is caused by infiltration and proliferation of activated immune cells including neutrophils, macrophages, fibroblasts, mast cells, NK cells, NKT cells, T-cells as well as plasma cells [
3]. Progressive joint and bone destruction is mediated through the activities of osteoclasts, chondrocytes, synovial fibroblasts and cytokine induction of destructive enzymes, chiefly matrix metalloproteinases (MMP) [
4]. Current therapy mainly aims to inhibit the biological function of tumor necrosis factor-alpha (TNF-α) and lymphocyte proliferation. Due to ineffectiveness of anti-TNF-α therapy in certain patients and various side effects of methotrexate which inhibits lymphocytes proliferation, there is still the need to identify new target molecules/pathways and to develop new treatment [
5]. Immunoregulatory and anti-inflammatory strategies that affect B-cell activation, T-cell activation or inhibit proinflammatory cytokines have recently shown great potential for the treatment of RA [
5,
6].
Human alpha-1 antitrypsin (hAAT) is a 52 kDa serum glycoprotein, synthesized primarily in the liver. It is also expressed in other types of cells including neutrophils, monocytes, macrophages, alveolar macrophages, intestinal epithelial cells, carcinoma cells and the cornea [
7‐
10]. The normal serum level of hAAT is 1-2mg/ml. During inflammation, hAAT level, as an acute phase reactant, can increase 3-4 folds, suggesting an important role in responding to inflammation in the human body. Increasing evidence indicates that hAAT is immunoregulatory, anti-inflammatory and may be used for the treatment of RA. It inhibits neutrophil elastase and proteinase 3 with high efficiency, as well as cathepsin G, thrombin, trypsin and chymotrypsin with lower efficiency [
11]. Most of these proteases target receptor proteins, involved in proinflammatory cytokine expression and cell signaling [
12]. It also has been reported that neutrophil elastase inhibitors reduce incidence as well as severity of collagen-induced arthritis (CIA) in both rats and mice [
13]. Human AAT is able to completely eliminate the acute inflammatory infiltration and connective tissue breakdown in the lung in a cigarette smoke-induced emphysema mouse model [
14]. It also inhibits lipopolysaccharide (LPS)-stimulated release of TNF-α and interleukin (IL) -1β, and enhances the production of anti-inflammatory cytokine IL-10 [
15‐
17]. Human AAT significantly protects against the lethality induced by TNF-α or endotoxin in mice [
18]. It can also induce expression of IL1-Ra in human peripheral blood mononuclear cells (PBMC's) [
19] and reduces ischemia-induced apoptosis and inflammation [
20]. We have recently shown, that combination therapy using doxycycline and hAAT gene therapy reduces arthritis development in mice, suggesting a therapeutic effect of hAAT in an arthritis mouse model [
21].
Recombinant adeno-associated virus vectors (rAAV) have been widely used for gene therapy in animal models and human clinical trials [
22], because of their unique features in safety and efficiency. It has been reported that rAAV mediated long-term and high levels of transgene expression in a wide variety of tissues, including muscle [
23], lung [
24], liver [
25], brain [
26] and eye [
27]. Recently developed rAAV vectors including new serotypes of AAV, mutants AAV and double stranded AAV have provided more opportunities and challenges for their application [
28‐
31]. Previously, we have shown hAAT gene therapy using rAAV2 and rAAV1 vectors prevented type 1 diabetes. However, the immune response to the transgene product (hAAT) complicated the therapeutic effect [
32,
33]. We have recently discovered that rAAV8 vector fail to transduce dendritic cells and induce immune tolerance to transgene product entailing rAAV8 as a promising vector used for therapeutic intervention [
34].
In the present study we further investigated the feasibility of hAAT with its anti-inflammatory and immunoregulatory properties for the treatment of RA using both, protein therapy and rAAV8 mediated gene therapy.
Methods
rAAV Vector Production
The rAAV-CB-hAAT vector construct was produced and packaged as previously described [
27]. Briefly, this vector carries hAAT cDNA driven by the cytomegalovirus (CMV) enhancer and chicken β-actin promoter and contains AAV2 inverted terminal repeats (ITRs). It was packaged into AAV serotype 8 capsid by cotransfection of vector plasmid and helper plasmid (XYZ8) into 293 cells. rAAV8-CB-hAAT vectors were purified by iodixanol gradient centrifugation followed by anion-exchange chromatography. The physical particle titers of vector preparations were assessed by dot blot analysis.
Animals
Six week-old male DBA/1 mice were purchased from Harlan Sprague Dawley, Inc. (Indianapolis, IN), housed in a specific pathogen-free room as approved by the University of Florida Institutional Animal Care and Use Committee. For induction of arthritis, bCII (Chondrex LLC, Redmond, WA) was dissolved in 0.05N acetic acid at a concentration of 2mg/ml by stirring overnight at 4°C and was emulsified with an equal volume of Complete Freund's Adjuvant (CFA) (Chondrex LLC, Redmond, WA). At the age of eight weeks, DBA/1 mice were immunized intradermally at the base of the tail with 0.1ml of emulsion containing 100 μg of type II collagen. Three weeks after priming (day 21), the mice were boosted with 0.1 ml of bCII (100 μg) emulsified in equal volume of incomplete Freund's Adjuvant (IFA) (Difco, Detroit, MI). For assessment of arthritis, all mice were monitored three times a week by the same person blinded to the treatment group and evaluated the incidence of arthritis and clinical score. An arthritis score system ranging from stage 0 - 4 was used: 0: no swelling or redness; 1: detectable arthritis with erythema; 2: significant swelling and redness; 3: severe swelling and redness from joint to digit; 4: joint stiffness or deformity with ankylosis [
35]. The clinical score was expressed as the average cumulative value of all four paws with a maximum score per animal of 16. Severe arthritis was defined as arthritis score > 3 for the purpose of comparing data between groups.
Histological Assessment
For the analysis of arthritis, mice were anesthetized and sacrificed by cervical dislocation on day 28 after immunization. The two hind limbs of mice in treatment and control groups were removed. Specimens were fixed in formalin and decalcified in RDO solution (Apex, Aurora, IL) for 10-20 min depending on tissue size and then checked manually for pliability. Sections 4 μm thick were cut and stained with hematoxylin and eosin according to standard methods.
Histological evaluation was performed by two independent and blinded pathologists. Infiltration of immune cells, hyperplasia, pannus formation and bone deformation was determined for each paw using an evaluation scale ranging from 0-3 according to severity of pathohistological changes. (0: normal, 1: mild, 2: moderate, 3: severe).
Human AAT Protein and rAAV8-CB-AAT Vector Administration
For hAAT protein therapy studies, DBA/1 mice were intraperitoneally (IP) injected with 0.5 mg (in 100 μl saline) of hAAT (Prolastin®, Bayer Corp., Elkhard, IN). The control group received saline injection. The injections were performed twice per week, starting at 6 days before the first bCII immunization until the end of study (EOS) at day 70 after the first immunization. For hAAT gene therapy studies, DBA/1 mice were IP injected with rAAV8-CB-hAAT vector (2 × 1011 particles/mouse) two weeks before the first CII immunization. The control group received saline injection.
ELISA for the Detection of Serum hAAT and BAFF Levels and Antibodies against hAAT, bCII and mCII
Detection of hAAT and anti-hAAT antibodies in mouse serum was performed as previously described [
32]. Purified hAAT (Athens Research & Technology, Athens, GA) was used as a standard. Anti-type II collagen antibodies in mouse serum were detected by a standard ELISA. Briefly, microtiter plates (Immulon 4, Dynex Technologies, Chantilly, VA) were coated with bCII or mCII (0.5 μg/well, Chondrex LLC, Redmond, WA) in Voller's buffer overnight at 4°C. After blocking with 3% bovine serum albumin, wells were incubated with samples at room temperature for 2 h. HRP-conjugated goat anti-mouse IgG antibodies (1:1,000 dilution, Sigma, St. Louis, MO), goat anti-mouse IgG1 antibodies (1:1,500 dilution, Roche, Indianapolis, IN) and goat anti-mouse IgG2a antibodies (1:1,500 dilution, Roche, Indianapolis, IN) were incubated for 1 h at RT. The plates were washed with PBS-Tween 20 between reactions. After adding the substrate (o-phenylenediamine, Sigma, St Louis, MO), plates were read at 490 nm on an MRX microplate reader (Dynex Technologies, Chantilly, VA). Optical densities were converted into units based on a standard curve generated with high titer sera from DBA/1 mice immunized with bCII. Detection of BAFF in serum was performed according to manufactures instructions (R&D systems, Inc. Minneapolis, MN).
Cell Culture
The murine macrophage cell line RAW 264.7 was cultured in serum free DMEM at 37°C in a 5% CO2 incubator. For measuring BAFF release into medium, cells were seeded at 1 × 105/ml in 12 well plates. Cells were incubated in quadruplicates with hAAT (0.5mg/ml; Prolastin®, Bayer Corp., Elkhard, IN) for 16 hours and BAFF secretion into the culture medium was determined by ELISA according to manufactures instructions (R&D systems, Inc. Minneapolis, MN).
Quantitative PCR
Total RNA from cell culture described above, was isolated using RNeasy Mini Kit (Quiagen, Valencia, CA). Samples were processed according to the manufacture's protocol. For reverse transcription, cDNA was synthesized with oligo dT16 primers and Moloney Murine Leukemia Virus Reverse Transcriptase (MMLV-RT) according to manufacture's manual (Taqman Reverse Transcription Reagents, Applied Biosystems, Foster City, CA).
cDNA was analyzed by quantitative PCR using gene-specific primers with SYBR Green 2X PCR mix (Applied Biosystems). The sequence of the primers were as follows: BAFF (205bp), sense: 5'-TGC CTT GGA GGA GAA AGA GA-3' and antisense: 5'-GGA ATT GTT GGG CAG TGT TT-3'; GAPDH (122bp), sense: 5'-CCT GGA GAA ACC TGC CAA GTA T-3' and antisense: 5'-TGC TGT TGA AGT CGC AGG A-3'. Reactions were set up in triplicate and performed on the ABI Prism 7700 Sequence Detector (Applied Biosystems). The cycling parameters were 2 min at 95°C for denaturation, 40 cycles of 15s at 95°C and 30 s at 60°C for amplification. The threshold cycle (CT) of each target product was determined, set to the log linear range of the amplification curve and kept constant for all data analysis. Data were analyzed with Sequence Detector Software (SDS). BAFF expression was normalized to the corresponding GAPDH values for the respective treatment. Values of BAFF expression following saline treatment are designated as 1. The experiment was repeated twice.
Assessment of T-cell Autoreactive Response
To test the effect of AAV8-hAAT gene therapy on splenocyte proliferation, spleens were harvested at 30 days after the first bCII immunization. Splenocytes were isolated and cultured in serum free X-VIVO medium (Cambrex, Walkersville, MD) in the presence or absence of bCII (100 μg/ml, Chondrex LLC, Redmond, WA). After 3 days culture, 1 μCi/well of [3H] TdR was added. Cells were cultured for additional 18h and [3H] TdR uptake was measured using a β- scintillation counter.
To measure cytokine release into the cell culture supernatant, a Beadlyte Mouse Multi-Cytokine Detection System 1 kit (Upstate, Temecula, CA, Cat # 48-005) was used according to the manufacture's instruction and in conjunction with the Luminex 100 system for cytokine determination.
Statistical Analysis
Data Analysis was performed using GraphPad Prism 4.0 (GraphPad Software) and SAS (SAS Institute). Student's t-test was used to compare differences in BAFF levels in culture medium as well as differences in mRNA expression levels. Mann-Whitney U-test was applied to analyze differences in stimulation indices, cytokine levels, pathohistological changes, serum levels of BAFF and antibodies. For comparison of arthritis score, area under the curve analysis was used and differences in arthritis incidence were determined using Kaplan-Meier survival curve and log-rank test. A p-value of p ≤ 0.05 was considered statistically significant.
Discussion
RA is a complex systemic autoimmune disease of unknown etiology. Although recently developed biologics that target TNF-alpha have provided dramatic improvement in controlling disease activity in many patients, continued searches for more efficient and safer treatments are still needed. In the present study we showed that hAAT, administered as protein or through rAAV8 mediated gene therapy, reduced levels of serum anti-CII auto-antibodies and B-cell activating factor (BAFF) and significantly delayed arthritis development in a mouse model.
Although the exact mechanisms underlying the therapeutic effect remain to be further investigated, several mechanisms may be involved. One is through the inhibition of proinflammatory cytokine production. It is well known that various proinflammatory cytokines, including TNF-α and IL1-β, play major roles in the pathogenesis of RA [
3]. Strategies targeting these cytokines have proven to be effective in treatment of RA [
38]. Previous work done by Janciauskiene and her colleagues clearly demonstrated that hAAT inhibited LPS-induced TNF-α, IL-6 and IL-1β production by human monocytes [
15,
16]. In addition, hAAT completely suppressed macrophage inflammatory protein-2 (MIP-2)/monocyte chemotactic protein-1 (MCP-1) gene expression in lung [
39]. Human AAT also enhanced anti-inflammatory cytokine IL-10 production from monocytes [
15]. As a consequence of interfering with the cytokine/chemokine network, hAAT may also inhibit polymorphonuclear leukocyte (PMN) invasion into the joint. Churg et al. demonstrated that hAAT inhibited silica-induced PMN influx into the lung and partially suppressed nuclear transcription factor B (NF-κB) translocation and increased inhibitor of NF-κB (I-⊠κB) levels in a mouse model of acute PMN mediated inflammation [
39]. Thus, it is possible that the effects of hAAT on pro-inflammatory cytokine production contribute to suppression of autoimmune-mediated inflammation.
In previous studies we showed that hAAT reduced anti-insulin auto-antibodies (IAA) and attenuated cell-mediated autoimmunity [
32,
33]. Consistent with these results, the present study showed that hAAT reduced the levels of anti-CII auto-antibodies and the IgG2a/IgG1 ratios of anti-CII auto-antibodies (mCII and bCII). We have observed that the effect of hAAT to suppress arthritis development is more profound in early stage of arthritis development. This is supported by the effect of hAAT on pathognomonic IgG2a antibody development at early time points (Fig.2) as well as the observation that mice eventually develop arthritis overtime. Therefore, hAAT maybe especially suitable for combination therapies. We did not observe significant effect of AAT on T-cell proliferation and cytokine production
in vitro (Figure
6A and
6B) indicating that AAT may have limited direct effect on T-cells. These data also suggest that AAT may more directly affect B-cell activity. Indeed, we have shown that AAT therapies significantly reduced B-cell activating factor of the TNF-α family (BAFF)
in vitro and
in vivo. BAFF is an important factor that modulates B-cell tolerance and homeostasis. It has been shown that soluble BAFF is elevated in serum and target organs of CIA model [
40] and BAFF antagonists suppressed arthritis development in murine models of rheumatoid arthritis [
41]. In addition, increased BAFF levels were found in serum of RA patients which correlated with serum levels of rheumatoid factor [
42]. The exact mechanism that AAT suppresses BAFF production remains to be elucidated.
Another possible mechanism of hAAT suppressing arthritis development is through inhibition of proteinases to prevent tissue injury and joint destruction. Human AAT is well known as a serine proteinase inhibitor (serpin). It inhibits proteinase 3, neutrophil elastase, and cathepsin G. These serine proteases are released by joint invading neutrophils following inflammatory stimuli and have shown to be involved in arthritis development [
12,
13,
43,
44]. Human AAT can also reduce ischemia-induced apoptosis, inflammation, and acute phase response in the kidney [
20]. We have recently shown that hAAT directly inhibits caspase 3 activity and protects islet cells from cytokine and chemically-induced apoptosis [
45].
In the protein therapy studies, we used Prolastin
®, which is clinical grade hAAT purified from human plasma. Repeated IP injection of hAAT induced strong humoral immune response against hAAT in DBA/1 mice (Figure
1B), similar to what has been observed in previous studies [
46,
47]. It is possible that non-specific inflammation caused by repeated IP injection is responsible for inhibition of arthritis. In order to rule out this possibility, we performed rAAV8 mediated hAAT gene therapy. AAV serotype 8 vector is unique for this purpose because it can mediate long term and high levels of transgene expression in the liver and muscle, but is not able to transduce dendritic cells and has low immunogenicity [
48,
49]. Indeed, after a single injection of rAAV8-CB-hAAT vector, sustained high levels of hAAT were detected in the circulation, while no detectable levels of anti-hAAT antibodies were present (Figure
3B) in contrast to mice that received hAAT protein therapy. These results are consistent with our recent observations in NOD mice and imply new applications of rAAV8 vectors [
34]. The detailed mechanism that rAAV8 vector mediates no immune response to the transgene product remains elusive. Importantly, we have observed protective effects and reductions of auto-antibodies by hAAT gene therapy. These results strongly support our hypothesis that hAAT is able to reduce inflammation in autoimmune diseases, such as RA and type 1 diabetes.
Competing interests
Christian Grimstein and Sihong Song may be entitled to future patent royalties from technology described in this paper.
Authors' contributions
CG conceived of the study, participated in its design, carried out animal experiments, cell proliferation assay, immunoassays, performed statistical analysis and drafted the manuscript. YKC conceived of the study, participated in its design and performed animal experiments and cell proliferation assay. CW helped performing cell proliferation assay, MS participated in discussion and helped to revise the manuscript, MA, MCT and MB participated in design and discussion of the study, SS conceived of the study participated in its design and helped to revise the manuscript. All authors read and approved the final manuscript.